ES2495266A1 - Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer - Google Patents

Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Download PDF

Info

Publication number
ES2495266A1
ES2495266A1 ES201330187A ES201330187A ES2495266A1 ES 2495266 A1 ES2495266 A1 ES 2495266A1 ES 201330187 A ES201330187 A ES 201330187A ES 201330187 A ES201330187 A ES 201330187A ES 2495266 A1 ES2495266 A1 ES 2495266A1
Authority
ES
Spain
Prior art keywords
igf
prognosis
early diagnosis
reagent
alzheimer disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330187A
Other languages
English (en)
Other versions
ES2495266B1 (es
ES2495266B8 (es
Inventor
Angel TRUEBA SAIZ
Ignacio Torres Aleman
Carmen CAVADA MARTINEZ
Angel NUÑEZ MOLINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Autonoma de Madrid filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201330187A priority Critical patent/ES2495266B8/es
Priority to EP14751079.6A priority patent/EP2957910A4/en
Priority to US14/767,490 priority patent/US20150374852A1/en
Priority to PCT/ES2014/070103 priority patent/WO2014125150A1/es
Publication of ES2495266A1 publication Critical patent/ES2495266A1/es
Publication of ES2495266B1 publication Critical patent/ES2495266B1/es
Application granted granted Critical
Publication of ES2495266B8 publication Critical patent/ES2495266B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/372—Analysis of electroencephalograms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/384—Recording apparatus or displays specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/40—Animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/42—Evaluating a particular growth phase or type of persons or animals for laboratory research
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)

Abstract

Uso de IGF-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer. La presente invención se refiere al uso del factor de crecimiento insulínico tipo 1 (IGF-1) como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer, así como a un kit que comprende IGF-1 y un sedante y su uso en el diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
    imagen2
ES201330187A 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Expired - Fee Related ES2495266B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
EP14751079.6A EP2957910A4 (en) 2013-02-13 2014-02-12 USE OF IGF-1 AS AN EARLY DIAGNOSTIC AND / OR PROGNOSTIC REAGENT FOR ALZHEIMER'S DISEASE
US14/767,490 US20150374852A1 (en) 2013-02-13 2014-02-12 Use of IGF-1 as a Reagent for Early Diagnosis and/or Prognosis of Alzheimer Disease
PCT/ES2014/070103 WO2014125150A1 (es) 2013-02-13 2014-02-12 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Publications (3)

Publication Number Publication Date
ES2495266A1 true ES2495266A1 (es) 2014-09-16
ES2495266B1 ES2495266B1 (es) 2015-06-25
ES2495266B8 ES2495266B8 (es) 2015-11-12

Family

ID=51353508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330187A Expired - Fee Related ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Country Status (4)

Country Link
US (1) US20150374852A1 (es)
EP (1) EP2957910A4 (es)
ES (1) ES2495266B8 (es)
WO (1) WO2014125150A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017470A (en) * 1984-10-29 1991-05-21 Chaovanee Aroonsakul Method of diagnosing alzheimer's disease and senile dementia
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
WO2002067764A2 (en) 2001-02-27 2002-09-06 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1817050B1 (en) * 2004-12-03 2015-04-15 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
CA2677339A1 (en) * 2007-02-08 2008-08-14 Powmri Limited Method of diagnosing a neurodegenerative disease
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome

Also Published As

Publication number Publication date
US20150374852A1 (en) 2015-12-31
EP2957910A4 (en) 2016-09-14
EP2957910A1 (en) 2015-12-23
WO2014125150A1 (es) 2014-08-21
ES2495266B1 (es) 2015-06-25
ES2495266B8 (es) 2015-11-12

Similar Documents

Publication Publication Date Title
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
ES2637421T3 (es) Composiciones tópicas que comprenden variantes de pliegue-OB
JP2014026276A5 (es)
JP2014026274A5 (es)
JP2014026275A5 (es)
JP2013212124A5 (es)
JP2015508051A5 (es)
JP2015509368A5 (es)
JP2014189812A5 (es)
JP2015107586A5 (es)
ES2540255A1 (es) Método de aislamiento de cuerpos apoptóticos
JP2016505534A5 (es)
ES2644847T3 (es) Máquina agrícola
ES2641554T3 (es) Kit de piezas para colocación de anclaje quirúrgico
JP2015127764A5 (es)
JP2014193955A5 (es)
ES2470816B1 (es) Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
ES2543850A2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
JP2014205658A5 (es)
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2495266A1 (es) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
ES2478692A1 (es) Formulaciones líquidas de carbocisteína de propiedades mejoradas
ES2523903B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
ES2642712T3 (es) Péptidos de foenixina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2495266

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150625

FD2A Announcement of lapse in spain

Effective date: 20210915